NCT03639324撤回1 期
Phase 1 Trial of Rituximab, Idelalisib, and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (RIVe-CLL/SLL)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 主要终点
- Find the RP2D of idelalisib and venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL)
研究概览
简要总结
To determine the recommended phase 2 dose (RP2D) of idelalisib and venetoclax in combination with rituximab in patients with relapsed or refractory Chronic lymphocytic leukemia/ Small lymphocytic lymphoma (CLL/SLL) following a lead-in period with idelalisib and rituximab
详细描述
This phase 1, multicenter, dose-escalation study is designed to find the Recommended Phase 2 Dose (RP2D) of idelalisib and venetoclax in combination with rituximab in patients with relapsed or refractory CLL/SLL and to assess the clinical activity of the combination with rituximab in patients with relapsed or refractory CLL/SLL and to assess the clinical activity of the combination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years of age. Relapsed or refractory B-cell CLL or biopsy-proven SLL. Treatment required in the opinion of the investigator
- •Must have had at least one standard treatment with a regimen containing at least one of the following agents/classes of agents; and where specified, must also meet the treatment duration, progression, and/or relapse criteria for that class of agent:
- •Fludarabine
- •An alkylator (eg, chlorambucil, bendamustine)
- •A BTK inhibitor (eg, ibrutinib, acalabrutinib); and must have progressed or relapsed > 6 months after last BTK inhibitor treatment
- •An anti-CD20 monoclonal antibody (eg, rituximab, obinutuzumab)
- •A BCL-2-family protein inhibitor (eg, venetoclax, navitoclax); and
- •if best response is < CR with BCL-2-family protein inhibitor treatment
- •must have had ≥ 1 year of BCL-2-family protein inhibitor treatment; and
- •must have progressed > 6 months after last BCL-2-family protein inhibitor treatment
- •if best response is CR with BCL-2-family protein inhibitor treatment
- •must have relapsed ≥ 1 year after last BCL-2-family protein inhibitor treatment
- •A PI3K inhibitor (eg, idelalisib, duvelisib, TGR-1202, copanlisib, buparlisib); and must have progressed or relapsed > 6 months after last treatment with the PI3K inhibitor (NOTE THAT THIS CRITERION IS NOT APPLICABLE TO 2ND-STEP REGISTRATION)
- •Prior allogeneic stem cell transplant allowed provided the following criteria are met:
- •≥ 12 months have elapsed since allogeneic transplant
- •No current or prior evidence of graft-versus-host disease
- •No current requirement for immunosuppressive therapy Prior autologous stem cell transplant allowed provided ≥ 6 months have elapsed since autologous transplant.
- •Eastern Cooperative Oncology Group performance status of 0, 1, or 2
- •Adequate bone marrow function as follows:
- •Absolute neutrophil count (ANC) ≥ 1,000/mm3 (without support of granulocyte colony stimulating factors)
- •Platelets ≥ 50,000/mm3 (untransfused)
- •Hemoglobin ≥ 9.0 g/dL
- •Adequate coagulation, renal, and hepatic function as follows:
- •aPTT and PT ≤ 1.2 × upper limit of normal (ULN) for the laboratory
- •Calculated creatinine clearance ≥ 50 mL/min as calculated by the standard Cockcroft-Gault equation using age, actual weight, creatinine, and gender
- •AST and ALT ≤ 1.5 × ULN for the laboratory
- •Bilirubin ≤ 1.5 × ULN for the laboratory. For a woman of childbearing potential (WCBP), a negative serum pregnancy test performed within 7 days prior to initiation of study treatment.
- •Note: Postmenopausal is defined as any of the following:
- •Age ≥ 60 years
- •Age < 60 years and amenorrheic for at least 1 year with follicle-stimulating hormone (FSH) and plasma estradiol levels in the postmenopausal range
- •Bilateral oophorectomy WCBP and male patients must agree to use a medically accepted form of birth control for the duration of study treatment and for at least 1 month following completion of venetoclax and/or idelalisib or 12 months following rituximab, whichever occurs later.
- •Ability to understand and the willingness to sign a written informed consent document.
排除标准
- •A patient who meets any of the following exclusion criteria is ineligible to participate in the study:
- •Known histologic transformation from CLL/SLL to an aggressive lymphoma (ie, Richter's transformation).
- •Known history of drug-induced pneumonitis History of inflammatory bowel disease. Central nervous system involvement Clinically significant infection including active hepatitis B or hepatitis C requiring active treatment, or active CMV infection Known human immunodeficiency virus (HIV) seropositivity. * Note: HIV testing is not required.
- •Vaccination within 4 weeks prior to initiation of rituximab *Note: Review vaccination status. Patients should, if possible, be brought up-to-date with all immunizations in agreement with current immunization guidelines at least 4 weeks prior to initiating rituximab.•Ongoing requirement for warfarin (due to potential drug-drug interactions that may increase the exposure of warfarin and ensuing complications).
- •Has received any of the following within 14 days prior to initiation of study treatment:(NOTE THAT THIS CRITERION IS NOT APPLICABLE TO 2ND-STEP REGISTRATION)
- •Anti-cancer therapy
- •Investigational therapy Has not recovered to ≤ grade 1 toxicity(s) from prior therapy, except for chronic residual toxicities that in the opinion of the investigator are not clinically relevant given the known safety/toxicity profiles of the study regimen (eg, alopecia). (NOTE THAT THIS CRITERION IS NOT APPLICABLE TO 2ND-STEP REGISTRATION) Has not recovered to ≤ grade 1 toxicity(s) from idelalisib and rituximab, except for chronic residual toxicities that in the opinion of the investigator are not clinically relevant given the known safety/toxicity profiles of the study regimen (eg, alopecia). (NOTE THAT THIS CRITERION IS NOT APPLICABLE TO 1ST-STEP REGISTRATION)
- •Ongoing or planned treatment with any of the following:
- •Steroid therapy for anti-neoplastic intent
- •Strong or moderate CYP3A inhibitor or inducer, and/or a narrow-therapeutic sensitive substrate
- •P-gp inhibitor or narrow-therapeutic sensitive P-gp substrate If any of these agents have been used, patients must be off them for ≥ 1 week before initiation of study treatment.
- •Prior intolerance to any component of study regimen that, in the opinion of the investigator would preclude study treatment.
- •A cardiovascular disability status of New York Heart Association Class ≥ II Diagnosis or treatment for another malignancy within 1 year of study registration, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, any in situ malignancy, or low-risk prostate cancer after curative therapy Active liver disease other than lymphoid involvement, inflammatory bowel disease, or Crohn's disease Malabsorption syndrome or other condition that precludes enteral route of administration.
- •Exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to:
- •Uncontrolled infection (viral, bacterial, or fungal)
- •Grade 3 or greater neutropenic fever within 1 week prior to initiation of study treatment Active autoimmune cytopenias (for 2 or more weeks), including autoimmune hemolytic anemia (AIHA) and idiopathic thrombocytopenic purpura.
- •Pregnancy or breastfeeding Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk, interfere with the patient's participation in the study or hinder evaluation of study results
研究组 & 干预措施
Dose Combination 1-1
Experimental
idelalisib + venetoclax
干预措施: Dose combination 1-1 (Drug)
Dose Combination 1-2
Experimental
idelalisib + venetoclax
干预措施: dose combination 1-2 (Drug)
Dose Combination 1-3
Experimental
idelalisib + venetoclax
干预措施: Dose combination 1-3 (Drug)
Dose Combination 1-4
Experimental
idelalisib + venetoclax
干预措施: dose combination 1-4 (Drug)
结局指标
主要结局
Find the RP2D of idelalisib and venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL)
时间窗: 41 Months
Determine the recommended phase 2 dose of idelalisib and venetoclax in combination with rituximab in patients with relapsed or refractory CLL/SLL following a lead-in period with idelalisib and rituximab.
次要结局
- Minimal residual disease (MRD) rate(52 Months)
- Progression Free Survival Rate(63 Months)
- Safety Evaluation: Determine adverse events (AEs) reported using criteria in the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0(63 Months)
- Determination of cumulative complete response (CR) rate.(52 Months)
- Summarize the objective response rate.(52 Months)
- Overall Survival Rate(63 Months)
- Pharmacokinetics of the combination of idelalisib and venetoclax.(7 Years)
研究者
相似试验
终止
2 期
Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell LymphomaMantle Cell LymphomaNCT05025423Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins7
Unknown
1 期
Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell LymphomaRelapsed Non Hodgkin LymphomaNCT03505944Nordic Lymphoma Group59
进行中（未招募）
2 期
A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone LymphomaMarginal Zone LymphomaNCT04416451Memorial Sloan Kettering Cancer Center6
撤回
2 期
Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Transformed Chronic Lymphocytic LeukemiaRefractory Transformed Chronic Lymphocytic LeukemiaRichter SyndromeTransformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell LymphomaTransformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell LymphomaNCT06247540Northwestern University
招募中
2 期
Rituximab Plus Venetoclax in Front Line Marginal Zone LymphomaMarginal Zone LymphomaMZLLymphomaNCT06510309Gottfried von Keudell, MD PhD33